MTOR and breast carcinoma: These results suggest that DMDD may be a potential therapeutic agent, with the downregulation of PI3K, Akt and mTOR representing a viable strategy for treating ER‐α positive MCF‐7 and triple‐negative MDA‐MB‐231 breast cancers.